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Abstract
Background: Activator protein 2 gamma (AP-2γ) is a member of the transcription factor activator
protein-2 (AP-2) family, which is developmentally regulated and plays a role in human neoplasia.
AP-2γ has been found to be overexpressed in most breast cancers, and have a dual role to inhibit
tumor initiation and promote tumor progression afterwards during mammary tumorigensis.
Methods:  To identify the gene targets that mediate its effects, we performed chromatin
immunoprecipitation (ChIP) to isolate AP-2γ binding sites on genomic DNA from human breast
cancer cell line MDA-MB-453.
Results: 20 novel DNA fragments proximal to potential AP-2γ targets were obtained. They are
categorized into functional groups of carcinogenesis, metabolism and others. A combination of
sequence analysis, reporter gene assays, quantitative real-time PCR, electrophoretic gel mobility
shift assays and immunoblot analysis further confirmed the four AP-2γ target genes in
carcinogenesis group: ErbB2, CDH2, HPSE and IGSF11. Our results were consistent with the
previous reports that ErbB2 was the target gene of AP-2γ. Decreased expression and
overexpression of AP-2γ in human breast cancer cells significantly altered the expression of these
four genes, indicating that AP-2γ directly regulates them.
Conclusion: This suggested that AP-2γ can coordinate the expression of a network of genes,
involving in carcinogenesis, especially in breast cancer. They could serve as therapeutic targets
against breast cancers in the future.
Background
The transcription factor activator protein-2 (AP-2) family
consists of AP-2α, AP-2β, AP-2γ, AP-2δ and AP-2ε; they are
retinoic acid inducible and developmentally regulated [1-
6]. The AP-2 protein forms a unique modular structure
containing an N-terminal proline- and glutamine-rich
Published: 11 August 2009
BMC Cancer 2009, 9:279 doi:10.1186/1471-2407-9-279
Received: 28 March 2008
Accepted: 11 August 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/279
© 2009 Ailan et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2009, 9:279 http://www.biomedcentral.com/1471-2407/9/279
Page 2 of 12
(page number not for citation purposes)
transactivational domain and a complex C-terminal helix-
span-helix motif necessary and sufficient for dimerization
and site-specific DNA binding. Through binding to a GC-
rich recognition sequence in the regulatory regions of
many genes, AP-2 protein provides a fundamental mech-
anism for regulating gene expression and involving into
lots of cellular processes [7,8]. AP-2 proteins have been
demonstrated to participate in the regulation of various
signaling pathways during development, cell growth, dif-
ferentiation and apoptosis by mouse knock-out studies
[9-15]. AP-2 proteins are also essential for maintaining
cellular homeostasis, and play a strict regulation role in
the battle between normal cell growth and neoplasia
[16,17].
AP-2 proteins have an essential role in the regulation of
normal breast development [18], and are also involved in
carcinogenesis, especially in breast cancer [19]. AP-2γ has
been shown to participate in the regulation of ErbB2 [1]
and estrogen receptor (ER) α [20], both of which contain
binding sequence of AP-2γ in their promoter region and
can promote tumorigenesis and metastasis [21]. On the
other hand, AP-2γ also induces p21 expression, arrests cell
cycle, and inhibits the tumor growth of human breast car-
cinoma cells [22,23]. These data suggest that there is a
dual role for AP-2γ in different mammary tumorigenic
stages: it initially delayed the appearance of tumors, how-
ever then accelerated tumor progression [23]. Taken
together, these findings provide evidence that AP-2γ par-
ticipates in a complex biologic dynamics, including cell
cycle progression, apoptosis, and tumor formation.
To further understand the complicated roles of AP-2γ
played in development and carcinogenesis, it is necessary
to search more downstream target genes regulated by AP-
2γ, and find out how they are regulated by AP-2γ. In this
study, we isolated the binding sites of AP-2γ on the whole
genomic DNA from human breast cancer cell line MDA-
MB-453 using chromatin immunoprecipitation (ChIP)
method. ChIP technique can identify the binding sites of
native transcription factors in a given cellular context and
reveal potential target genes. We found 20 novel binding
sites of AP-2γ in the genomic DNA of MDA-MB-453 cells.
These sites are associated with genes involved in the regu-
lation of carcinogenesis, metabolism or others. A combi-
nation of sequence analysis, reporter gene assays,
electrophoretic gel mobility shift assays, quantitative real-
time PCR (Q-RT-PCR), and immunoblot analysis vali-
dated and further defined the binding sites on four target
genes (ErbB2, CDH2, IGSF11 and HPSE) in carcinogene-
sis group. The expressions of these four genes were con-
firmed to be significantly altered by silencing or
overexpression of AP-2γ. Moreover, Q-RT-PCR analysis
revealed the effect of transcriptional enhancing or sup-
pression by AP-2γ for different genes. The novel target
genes of AP-2γ might be used as therapeutic targets against
breast cancer in the future.
Methods
Cell culture
Human breast cancer cells MDA-MB-453, MDA-MB-231
and HBL-100 were cultured under conditions of 37°C
and 5% CO2  in RPMI 1640 (Gibco, Rockville, MD,
Carlsbad, USA) supplemented with 10% fetal bovine
serum, 100 U/ml penicillin, 100 μg/ml streptomycin and
5 μg/ml insulin.
Chromatin immunoprecipitation (ChIP) assay
ChIP assay was performed using the EZ ChIP™ Kit (Cata-
log # 17–371, Upstate Biotechnology, Boston, USA)
according to the manufacturer's instruction. Briefly, cells
were grown on 100 mm plates to 85% confluence; formal-
dehyde was added to a final concentration of 1%, and the
plates were incubated for 10 min at 37°C; the cross-link-
ing reaction was stopped by the addition of 100 mM gly-
cine containing protease inhibitors (Boehringer cocktail,
Ingelheim, Germany). Cells were then collected by cen-
trifugation and lysed in SDS lysis buffer (1% SDS, 10 mM
EDTA, 50 mM pH 8.0 Tris-HCl, and protease inhibitors);
after sonication, DNA was sheared into 0.3–2 kb frag-
ments; insoluble materials were removed by centrifuga-
tion. The extracts were diluted 10-fold in ChIP dilution
buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA,
16.7 mM pH 8.1 Tris-HCl, and 167 mM NaCl) and pre-
cleared by incubation with Salmon Sperm DNA-Protein A
coated agarose beads to reduce nonspecific interactions.
The precleared supernatants were incubated with 2 μg of
rabbit polyclonal anti-AP-2γ antibody (sc-8977, Santa
Cruz Biotech, Delaware, USA), or 2 μg of normal rabbit
IgG (Catalog # 12-371B, Upstate Biotechnology) over-
night at 4°C; immune complexes were collected using
Salmon Sperm DNA-Protein A coated agarose beads. The
immunoprecipitated complexes were washed once in low
salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM
EDTA, 20 mM pH 8.1 Tris-HCl, and 150 mM NaCl), once
in high salt wash buffer (0.1% SDS, 1% Triton X-100, 2
mM EDTA, 20 mM pH 8.1 Tris-HCl, and 500 mM NaCl),
once in LiCl wash buffer (0.25 M LiCl, 1% IGEPAL-
CA630, 1% Sodium deoxycholate, 1 mM EDTA, and 10
mM pH 8.1 Tris-HCl) and twice in TE buffer (10 mM Tris-
HCl, 1 mM EDTA, pH 8.0). Following extensive washing,
the cross-linked DNA-protein complexes were eluted
using 1% SDS, 0.1 M NaHCO3 and dissociated by incuba-
tion at 65°C for 4–5 hours. After treatment with RNase A
(Roche Applied Science, Basel, Switzerland) and protein-
ase K (Roche Applied Science), DNA was purified using
the Qiagen MinElute kit; the purified DNA fragments can
be used directly for PCR amplification of the genomic
fragments of interest, or cloned as pUC19-ChIP-DNA for
sequencing and further experiments.BMC Cancer 2009, 9:279 http://www.biomedcentral.com/1471-2407/9/279
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AP-2γ-ChIP-fragment luciferase vectors
AP-2γ-ChIP fragments were excised from pUC19-ChIP-
DNA plasmids and inserted into pTAL-Luc vector (Clon-
tech, Mountain view, USA) using KpnI and XhoI sites. Site-
directed mutagenesis was performed on the GCCN3 GGC
motif within the putative AP-2γ binding sites of R1-15,
R3-36 and R4-28 fragments. Primers (Table 1) corre-
sponding to both strands with mutated bases in the mid-
dle were designed to produce mutant R1-15, R3-36 and
R4-28 by overlapping extension PCR [24]. Briefly, in the
first PCR, two parallel reactions were performed using
pTAL-ChIP-DNA vectors as template: one with vector
sense primer upstream of insert and mutated insert anti-
sense primer, the other with mutated insert sense primer
(complementary to the mutated insert antisense primer)
and vector antisense primer downstream of insert; the
equal molar mixture of these two PCR products was taken
as template for the second PCR using the two vector prim-
ers. Final PCR product was subcloned into upstream of
the firefly luciferase gene at KpnI/XhoI sites of pTAL-Luc
vector. All constructs were sequencing confirmed, and we
numbered the position of the AP-2γ binding site in the
AP-2γ-ChIP fragments.
Transient transfections and reporter gene assays
In 100 mm culture dishes, HBL-100 and MDA-MB-231
cells were grown to 80% confluence and transfected with
12 μg of pCMV-Myc-AP-2γ or pCMV-Myc, MDA-MB-453
cells were grown to 85% confluence and transfected with
600 pmol of AP-2γ siRNA or scramble siRNA. Twenty four
hours after transfection, the cells were collected to prepare
total RNA and protein lysates for quantitative real-time
PCR and immunoblot analysis of reporter genes. The siR-
NAs (purchased from Shanghai GenePharma) were as fol-
lows: AP-2γ siRNA (sense), 5'-GCUCUACGUCUAAAU
ACAATT-3'; AP-2γ siRNA (antisense), 5'-UUGUAUUUA-
GACGUAGAGCTG-3'; scramble siRNA (sense), 5'-
UUCUCCGAACGUGUCACGUTT-3'; scramble siRNA
(antisense), 5'-ACGUGACACGUUCGGAGAATT-3'.
For luciferase assays, MDA-MB-453, MDA-MB-231 and
HBL-100 cells were seeded at an initial density of 2 × 105
cells/well in 12-well plates, then transfected with 600 ng
of the luciferase reporter constructs and 600 ng of pCMV-
Myc-AP-2γ or pCMV-Myc. 400 ng of pCMV-LacZ were
used as internal reference to monitor transfection effi-
ciency. Twenty four hours after transfection, the cells were
lysed, and luciferase assays were performed using the
Promega Luciferase Assay system. All data were from
duplicate of at least three independent experiments.
Electrophoretic gel mobility shift assays
The oligonucleotides containing wild-type or mutated
binding sites of transcription factor AP-2γ were synthe-
sized; and the wild-type consensus sequences of AP-2γ
binding site on the promoter of human metallothionein
IIa was used as competitor DNA (Table 1). The forward
oligonucleotides were end-labeled with [γ-32P] ATP using
T4 polynucleotide kinase, and combined with unlabeled
reverse oligonucleotide after purification (QIAquick
Nucleotide Removal Kit). The annealing mixture was
heated to 95°C for 10 min, and cooled down slowly to
room temperature to form probes. Vector pGEX-4T-2
(Amersham) was used to express GST-AP-2γ fusion pro-
teins. 5 pmol of labeled probes were incubated with 50
pmol of purified recombinant GST-AP-2γ protein for 20
Table 1: Oligonucleotides used for site-directed mutagenesis and electrophoretic mobility shift assay (EMSA)
Name Sequence 5'-3' Name pTAL-Luc vector
WtR3-36/HPSE(F) GGTACCGGCCTGGACTGCAGACCT
WtR3-36/HPSE(R) CTCGAGGCATGCCTGCAGGTCAAA pTAL-R3-36/HPSE
WtR4-28/CDH2(F) GGTACCCTGCGATGGGGGAGAACA
WtR4-28/CDH2(R) CTCGAGTCCCCCCACGAGAAAAAA pTAL-R4-28/CDH2
WtR1-15/IGSF11(F) GGTACCTTCTGTCATTTTGGGTCT
WtR1-15/IGSF11(R) CTCGAGTGGTTTTATCTGTGTAAT pTAL-R1-15/IGSF11
WtR3-1/ErbB2 (F) GGTACCGTAAAACGACGGCCAG
WtR3-1/ErbB2 (R) CTCGAGAGGAAACAGCTATGAC pTAL-R3-1/ErbB2
WtR3-36-648/HPSE(F) AAAAGTGCCCAGAGCCCATGA
MtR3-36-648/HPSE(F) AAAAGTattCAGgGCCCATGA pTAL-R3-36-648/HPSE
WtR3-36-676/HPSE(F) AATGTGGCCCTGGTCACTTAG
MtR3-36-676/HPSE(F) AATGTGattCTGaTCACTTAG pTAL-R3-36-676/HPSE
WtR4-28-854/CDH2(F) ATGCGACCTGCAGGCATGCCA
MtR4-28-854/CDH2(F) ATGCGACCcGCAaatATGCCA pTAL-R4-28-854/CDH2
WtR1-15-286/IGSF11(F) TTTGCTGCCTTTGTCCTGTAG
MtR1-15-286/IGSF11(F) TTTGCTattTTTaTCCTGTAG pTAL-R1-15-286/IGSF11
HMT AACGGACCGCCCGCGGCCCGT
Note:  Only sense strands for oligonucleotides used in EMSA were shown; underlined parts were the putative binding sites, and mutated 
nucleotides were denoted as the lowercase letters. (F): forward primer; (R): reverse primer.BMC Cancer 2009, 9:279 http://www.biomedcentral.com/1471-2407/9/279
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min at 37°C in 15 μl of reaction buffer: 10 mM HEPES
(pH 8.0), 60 mM KCl, 4 mM MgCl2, 0.1 mM EDTA, 100
μg/ml BSA, 0.25 mM DTT, and 10% glycerol; then were
resolved on 6% non-denaturation polyacrylamide gels.
After drying, gels were exposed to Kodak X-ray film at -
80°C, and signals were detected by autoradiography.
Competition reactions were performed by pre-incubating
the GST-AP-2γ protein with 10- or 50-fold of excess unla-
beled competitor DNA prior to addition of the radioactive
probes.
Quantitative real-time PCR (Q-RT-PCR)
Total RNA was isolated from mammary-derived cell lines
with Trizol reagent (Invitrogen, Carlsbad, CA), and con-
taminated chromosomal DNA was removed by RNase-
free DNase treatment. cDNA was synthesized from 2 μg of
total RNA using Oligo (dT)18 Primer according to the
manufacturer's instruction (Fermentas, Vilnius, Lithua-
nia). Then gene expressions were analyzed by quantitative
real-time PCR (Q-RT-PCR) using 5 ng of reverse-tran-
scribed total RNA template. The amplified products were
detected with SYBR Green (ABI, San Francisco, USA) in
combination with a melting curve analyses to ensure spe-
cificity (7900 HT Fast Real-time PCR System), and Delta
Ct Method was used for quantification. The primer
sequences were as follows: AP-2γ sense, 5'-GCCATCT-
CATTTCGTCCTCC-3'; AP-2γ antisense, 5'-GCCATCT-
CATTTCGTCCTCC-3'; ErbB2 sense, 5'-
GAGACCCGCTGAACAATACC-3'; ErbB2 antisense, 5'-
TGGATCAAGACCCCTCCTTT-3'; IGSF11 sense, 5'-
GACTTGGGCCAATCTTTCTC-3'; IGSF11 antisense, 5'-
TGTGGTGATGACCCTCTGTT-3'; CDH2 sense, 5'-
ACCAGGTTTGGAATGGGACA-3'; CDH2 antisense, 5'-
ACATGTTGGGTGAAGGGGTG-3'; HPSE sense, 5'-
TTGCTATCCGACACCTTTGC-3'; HPSE antisense, 5'-
CACGCTTGCCATTAACACCT-3';  β-actin sense, 5'-
GCGCGGCTACAGCTTCA-3';  β-actin antisense, 5'-
CTTAATGTCACGCACGAT TTCC-3'. The reactions yielded
a 433-bp PCR product for AP-2γ, a 109-bp PCR product
for ErbB2, a 119-bp PCR product for IGSF11, a 156-bp
PCR product for CDH2, a 210-bp PCR product for HPSE
and a 60-bp PCR product for β-actin. All experiments were
preceded in triplicate.
PCR amplification
Standard PCR was carried out to determine the specificity
of AP-2γ binding DNA fragments derived from the AP-2γ-
ChIP and normal rabbit IgG negative control. The ChIP-
DNA fragments from MDA-MB-453 cells were amplified
under conditions of 16.6 mM (NH4)2SO4, 0.67 mM Tris
(pH8.8), 6.7 mM MgCl2, 10 mM β-mercaptoethanol, 10%
dimethyl sulfoxide, 1.5 mM nucleotides, and 1.25 U of
Taq polymerase. PCR products were resolved on a 1% aga-
rose gel, and stained with ethidium bromide. The primer
sequences were as follows: R4-28/CDH2-271 bp, (F) 5'-
ATTTCCAAGTGGCTGAGGCA-3', (R) 5'-TGAACCATT-
GATTACGCCCA-3'; R1-15/IGSF11-291 bp, (F) 5'-GCAT-
TCTGTCATTTTGGGTC-3', (R) 5'-
CAACAACAATGGGTTCCTTC-3'; R3-36/HPSE- 260 bp,
(F) 5'-GGCAGAAGGGCATAGTGTCT-3', (R) 5'-CAG-
GGATGTGGGCTAAGTGA-3'; R3-1/ErbB2-227 bp, (F) 5'-
GTAAAA CGACGGCCAGT-3', (R) 5'-AGGAAACAGCTAT-
GAC-3'.
Western blot
Cell pellets were lysed in RIPA buffer (50 mM Tris-HCl
(pH 7.2), 150 mM NaCl, 1% (w/v) Triton X-100, 1% (w/
v) sodium deoxycholate, 0.1% (w/v) SDS) containing
protease inhibitors (Boehringer cocktail). Then the pro-
teins were subjected to electrophoresis on 10% SDS- poly-
acrylamide gel, and detected by western blot using rabbit
polyclonal antibodies: anti-AP-2γ (sc-8977, 1:200), anti-
ErbB-2 (sc-284, 1:200), anti-HPSE (sc-25825, 1:200), and
anti-CDH2 (BA0673, 1:200). GAPDH (Mab-2005079,
1:2000) was used as loading control.
Results
ChIP assay identifies novel genomic binding sites for AP-2γ 
associated with genes involving carcinogenesis in MDA-
MB-453 breast cancer cells
To investigate the expression of AP-2γ in breast cancer cell
lines, we performed RT-PCR (Figure 1A) and immunoblot
analysis (Figure 1B) in MDA-MB-453, MDA-MB-231 and
HBL-100 cells. The results indicated that AP-2γ was highly
expressed in MDA-MB-453 cells, but only lowly expressed
in MDA-MB-231 and HBL-100 cells.
So we used ChIP assay to isolate AP-2γ binding sites in its
target genes from MDA-MB-453 cells. Protein/DNA com-
plexes were immunoprecipitated using polyclonal anti-
AP-2γ antibody; Normal rabbit IgG and without antibody
AP-2γ highly expressed in MDA-MB-453 cells, but only lowly  expressed in MDA-MB-231 and HBL-100 cells Figure 1
AP-2γ highly expressed in MDA-MB-453 cells, but 
only lowly expressed in MDA-MB-231 and HBL-100 
cells. A. Expression of AP-2γ detected by RT-PCR. B. 
Expression of AP-2γ detected by immunoblot analysis. Lane 
1, MDA-MB-453 cells. Lane 2, MDA-MB-231 cells. Lane 3, 
HBL-100 cells. Housekeeping genes β-actin and GAPDH 
were used as internal controls.BMC Cancer 2009, 9:279 http://www.biomedcentral.com/1471-2407/9/279
Page 5 of 12
(page number not for citation purposes)
were taken as negative controls. The immunoprecipitated
DNA fragments were cloned into pUC19 vector for blue/
white screening. Forty clones from AP-2γ-ChIP-derived
DNA fragments were obtained and sequenced, whereas
no clones were found from negative controls.
The inserted AP-2γ-ChIP-derived DNA fragments ranged
from 300 bp to 2 kb; their sequences were mapped to
human genome using BLAST algorithm (Additional file
1). Genes near to these 40 ChIP fragments were deter-
mined using GeneHuggers, a bioinformatics program
which enables precise selection of subsequence regions
from records of the RefSeq human genome database
based on diverse criteria. Through combination search of
BLAST and GeneHuggers, we found multiple clones for
eight fragments, and one of them was well known to con-
tain AP-2γ binding sites before. 20 novel AP-2γ-ChIP frag-
ments were mapped in proximity to known or predicted
genes (Table 2). Within them, six fragments located at the
intronic region of a gene, three fragments located at the
downstream region of a gene, but about sixty percent (12
of 21) of fragments located at the upstream region of a
gene; this suggested a binding preference of AP-2γ is the
upstream region of a gene.
The genes near to AP-2γ-ChIP fragments were considered
as potential targets for AP-2γ binding and regulation. They
were grouped into different functional categories (Table
2), which involved in the regulation of carcinogenesis,
metabolism or others. Fragments appeared in multiple
clones were R1-7/GALK1, R3-36/HPSE, R4-8/HIVEP1, R3-
14/APOL3, R2-2/TMEM148, R2-7/LOC401864, R3-1/
ErbB2 and R4-28/CDH2, in which R3-1/ErbB2 was well
known to contain AP-2γ binding sites before [1,25].
Genes involved in the regulation of carcinogenesis
include IGSF11, HPSE, CDH2 and ErbB2 (Additional files
2, 3, 4 and 5). Considering the role of AP-2γ in carcino-
genesis, we chose these four genes for further investigation
to elucidate their functions in breast cancer.
AP-2γ upregulates the transcription activity through 
binding to ErbB2, CDH2, HPSE and IGSF11
At least two independent ChIP experiments were per-
formed to confirm the binding of AP-2γ to the four iso-
lated ChIP fragments near to genes ErbB2, CDH2, HPSE
and IGSF11, the related PCR products were detected from
input samples and AP-2γ-ChIP-derived DNA samples, but
not from IgG-ChIP-derived DNA samples (Figure 2).
Transcription factor AP-2γ binding sites near to genes
ErbB2, CDH2, HPSE and IGSF11 were predicted by JAS-
PAR program and MatInspector program http://
www.genomatix.de utilizing TRANSFAC matrices (core
similarity 1.0 and matrix similarity 0.9). We found one
consensus binding site in R3-1/ErbB2 (644 to 652), two
consensus binding sites in R3-36/HPSE (648 to 656, and
Table 2: Categories of putative AP-2γ target genes
Fragment/Gene Carcinogenesis GeneBank accession no Chromosome location Distance from gene (kb) location
R1-15/IGSF11 NT_005612.15 3q13.3 * Intron 3
R3-36/HPSE NT_016354.18 4q21 23 5'
R4-28/CDH2 NT_010966.13 18q11.2-12 103 5'
R3-1/ErbB2 NT_010755 17q11.2-q12 1 5'
Catalytic activity/metabolism
R1-7/GALK1 NT_010641.15 17q24 4.5 5'
R4-21/MAT2B NW_922784.1 5q34 1 5'
R1-11/UPP1 NT_007819.16 7p12-13 30 3'
R1-2/SQRDL NT_010194.16 15q21 50 3'
R4-25/ACOT7 NT_021937.18 1p36.2 * Intron 2
others
R4-8/HIVEP1 NW_922984.1 6p23-24 42 5'
R3-2/CNTNAP2 NW_923707.1 7q35-36 * Intron 1
R3-14/APOL3 NT_011520.11 22q12-13 16.5 5'
R2-13/AAK1 NT_022184.14 2p12-14 3 5'
R1-9/SEMA6D NW_925884.1 15q12 1 5'
R3-26/HEL308 NW_922162.1 4q21 48 3'
R1-26/EMR1 DQ217942.1 19p13.2 1 5'
R3-35/ALG14 NW_921795.1 1p21-22 * Intron 1
unknown
R1-1/SIPA1L2 NT_004559.13 1q26 * Intron3
R4-20/FRY NT_024524.13 13q12-13 * Intron 3
R2-2/TMEM148 NT_010498.15 16q22 49 5'
R2-7/LOC401864 NT_010498.15 16q24 1 5'
* The fragment is part of the gene.BMC Cancer 2009, 9:279 http://www.biomedcentral.com/1471-2407/9/279
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676 to 684), one consensus binding site in R4-28/CDH2
(854 to 862), and one consensus binding site in R1-15/
IGSF11 (286 to 294). To clarify how AP-2γ regulates the
gene expression of ErbB2, CDH2, HPSE and IGSF11
through binding to the predicted sites, wild-type and
mutant of AP-2γ-ChIP fragment luciferase vectors were
generated through appropriate restriction enzyme diges-
tion and overlapping extension PCR (Figure 3). Because
ErbB2 has previously been characterized as an AP-2γ target
gene [21], the mutant of ErbB2 luciferase vector was not
included.
Reporter gene assays were performed to check the tran-
scription activity. Related wild-type or mutant luciferase
constructs were cotransfected with pCMV-Myc-AP-2γ or
pCMV-Myc into MDA-MB-453, MDA-MB-231, and HBL-
100 cells; and the reporter gene luciferase activity was
assayed. pCMV-LacZ was also cotransfected in all experi-
ments, and β-galactosidase activity was used to normalize
transfection efficiency. As shown in Figure 4, AP-2γ upreg-
ulated the expression of four genes (R3-1/ErbB2, R4-28/
CDH2, R3-36/HPSE and R1-15/IGSF11) to about 2~3
folds (Bars marked by asterisk). However, the binding site
of R3-36/HPSE (676 to 684) is not functional; the
decrease of luciferase activity is not statistically significant
(Figure 4C).
Identification of putative AP-2γ binding sites on genes 
CDH2, HPSE and IGSF11
To further define the sequence elements for AP-2γ bind-
ing, we conducted electrophoretic gel mobility shift assays
(EMSA) using 32P-labeled probes corresponding to the
potential AP-2γ binding motifs in AP-2γ-ChIP fragments.
As shown in Figure 5, purified recombinant GST-AP-2γ
protein binds to wild-type oligonucleotides WtR3-36-
648/HPSE, WtR4-28-854/CDH2 and WtR1-15-286/
IGSF11, but not to mutated oligonuleotides MtR3-36-
648/HPSE, MtR4-28-854/CDH2 and MtR1-15-286/
IGSF11. The specificity of such bindings was also con-
firmed by competition experiments with excess wild-type
consensus sequence of AP-2γ binding site in HMTIIa pro-
moter (HMT). After treatment with 10- or 50-fold of
excess unlabeled oligonucleotides HMT, these DNA-pro-
tein bindings were markedly decreased. Both wild-type
oligonucleotides WtR3-36-676/HPSE and mutated oli-
gonuleotides MtR3-36-676/HPSE did not produce
retarded bands, indicating that the sequence element
HPSE (676–684) is not the functional binding site of AP-
2γ. Because the mutation of the AP-2γ binding site in
ErbB2 has also previously been demonstrated to lead to a
significant decrease of their binding in an EMSA experi-
ment [26], ErbB2 was not included in 5
AP-2γ-dependent regulation of candidate target genes at 
mRNA and protein level
To make sure whether the genes associated with the frag-
ments identified by ChIP assays are functional targets of
AP-2γ or not, endogenous AP-2γ suppression experiment
by RNA interference was performed in MDA-MB-453 cells
AP-2γ binds to genomic DNA fragments near to ErbB2,  CDH2, HPSE and IGSF11 genes in vivo Figure 2
AP-2γ binds to genomic DNA fragments near to 
ErbB2, CDH2, HPSE and IGSF11 genes in vivo. Nor-
mal rabbit IgG and rabbit polyclonal anti-AP-2γ antibody 
were used to immunoprecipitate protein-bound DNA in 
MDA-MB-453 cells. The immunoprecipitated genomic DNA 
was subjected to PCR amplification using primers flanking the 
AP-2γ response elements. Genomic DNA (Input) without 
immunoprecipitation was used as positive controls, and 
housekeeping gene β-actin was used as negative control.
Diagram of luciferase vectors of wild-type and mutant AP-2γ- ChIP-fragments Figure 3
Diagram of luciferase vectors of wild-type and 
mutant AP-2γ-ChIP-fragments. Wild-type or mutant 
AP-2γ-ChIP-fragment was cloned into the pTAL-Luc vector 
for luciferase assay. The wild-type binding sites of AP-2γ 
were indicated by oval, and the mutated sites were indicated 
by cross (X).BMC Cancer 2009, 9:279 http://www.biomedcentral.com/1471-2407/9/279
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and overexpression experiment by transient transfection
of AP-2γ were performed in HBL-100 cells and MDA-MB-
231 cells (Figure 6). Q-RT-PCR data from at least three
independent experiments were calculated with Delta Ct
Method.
In MDA-MB-453 cells transfected with AP-2γ siRNA, AP-
2γ mRNA levels showed an about 3-fold decrease (Figure
6A). Accordingly, the mRNA levels of ErbB2, CDH2, HPSE
and IGSF11 also dramatically decreased 2~3-fold. In HBL-
100 cells, while AP-2γ mRNA levels increased about 7.5-
fold (Figure 6B), the HPSE mRNA level increased, but the
ErbB2, CDH2 and IGSF11 mRNA levels remained
unchanged. In MDA-MB-231 cells, while AP-2γ mRNA
levels increased about 2.5-fold (Figure 6C), the mRNA
levels of ErbB2, CDH2, HPSE and IGSF11 were then dra-
matically up-regulated about 4~8-fold.
In MDA-MB-453 cells transfected with AP-2γ siRNA, fol-
lowing with the decrease of AP-2γ protein level, the pro-
tein levels of ErbB2, CDH2 and HPSE were also
dramatically down-regulated (Figure 7, Lane 2). While
overexpressing AP-2γ protein in MDA-MB-231 cells, the
protein levels of ErbB2, CDH2 and HPSE were dramati-
Over-expression of AP-2γ significantly upregulated the transcription activities of ErbB2, CDH2, HPSE and IGSF11 Figure 4
Over-expression of AP-2γ significantly upregulated the transcription activities of ErbB2, CDH2, HPSE and 
IGSF11. Luciferase vectors of wild-type or mutant AP-2γ-ChIP-fragments were cotransfected with pCMV-Myc-AP-2γ or 
pCMV-Myc into MDA-MB-453, MDA-MB-231, and HBL-100 cells, and luciferase gene expression was assayed. A. Wild-type 
R3-1/ErbB2 was upregulated by AP-2γ in different breast cancer cells. B. Mutation on AP-2γ binding site of CDH2 abrogated 
the upregulation by AP-2γ. C. Disruption of binding site on R3-36/HPSE (648–656) reduced the upregulation of HPSE by AP-2γ; 
"however the binding site on R3-36/HPSE (676–684) is not functional. D. Mutation of binding site R1-15-286/IGSF11 inhibited 
the upregulation of IGSF11 by AP-2γ in different breast cancer cells. The relative luciferase activity in each sample was normal-
ized and presented as mean ± SD from triplicated independent experiments. (* means P < 0.01).BMC Cancer 2009, 9:279 http://www.biomedcentral.com/1471-2407/9/279
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cally increased (Figure 7, Lane 6). However, in HBL-100
cells, overexpression of AP-2γ protein only significantly
increased HPSE protein level, the protein level of ErbB2
and CDH2 remained unchanged (Figure 7, Lane 4). As
IGSF11 antibody is not commercially available, we didn't
check the protein level changes by the alteration of AP-2γ
expression.
Discussion
In post-genome era, studying the gene expression and reg-
ulation in eukaryotic cells becomes more and more
important. The genomic DNA exists in eukaryotic cells as
chromatin, which is a dynamic structure could control the
access of transcription factors to DNA binding sites, influ-
ences the interactions between different transcription fac-
tors, and mediates their subnuclear localization [27,28].
So studying the interaction between proteins such as tran-
scription factors and genomic DNA at its chromatin status
is very critical for elucidating the regulation mechanism of
gene expression. Chromatin immunoprecipitation (ChIP)
is a method used to determine the location of DNA bind-
ing sites on the genome for a particular protein of interest.
This technique gives a picture of the protein-DNA interac-
tions that occur inside the nucleus of living cells or tissues.
Although there are more methods to study the interac-
tions between transcription factors and genomic DNA,
this is the only real in vivo approach. Using ChIP assay to
isolate AP-2γ binding sites from accessible regions of
native chromatin in MDA-MB-453 breast cancer cells
allowed us to identify a number of AP-2γ target genes as
well as to find out how AP-2γ affect these gene expressions
in living cells.
In this study, we have isolated forty clones from AP-2γ-
ChIP-derived genomic DNA fragments; we did not obtain
any clones from the negative controls indicating a low rate
of false positive clones. Among the forty clones, eight frag-
ments were found within multiple clones, and one of
these fragments (R3-1/ErbB2) has previously been shown
to contain functional AP-2γ binding sites. The binding of
AP-2γ to the isolated ChIP fragments was confirmed using
independent ChIP assays (Figure 2), emphasizing the reli-
ability of our findings. The four AP-2γ binding fragments
examined in more detail (associated with genes ErbB2,
CDH2 IGSF11 and HPSE) could all be stimulated by co-
expression of AP-2γ in reporter assays (Figure 4), and were
able to bind to recombinant protein GST-AP-2γ (Figure
5).
Electrophoretic gel mobility shift assays Figure 5
Electrophoretic gel mobility shift assays. GST-AP-2γ fusion protein was incubated with 32P-labeled wild-type or mutated 
oligonucleotides (marked by asterisk). The protein-DNA bindings were also confirmed by competition experiments with unla-
beled AP-2γ consensus binding sequence in human metallothionein IIa promoter (HMT). The retarded bands showed positive 
binding results, and the intense bands at the bottom were unbound labeled probes. Data confirmed the binding elements on 
HPSE, CDH2 and IGSF11.BMC Cancer 2009, 9:279 http://www.biomedcentral.com/1471-2407/9/279
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All four of the genes validated here were found to be pos-
itively regulated by AP-2γ. However, examination of the
regulation of expression of the remaining 17 novel candi-
date genes, using Q-RT-PCR to examine both AP-2γ over-
expressing MDA-MB-231 cells and AP-2γ silenced MDA-
MB-453 cells, has shown that some of the genes
(LOC401864, SEMA6D, STPA1L2, and FRY) identified in
the screen can be negatively regulated by AP-2γ (Addi-
tional file 6). Thus, the ChIP-cloning assay described here
has successfully identified both activated and repressed
genes; however more work is still required to further
define how AP-2γ regulates these 17 potential target
genes.
AP-2γ has been reported to participate into the regulation
of breast cancer initiation and progression [21,29,30].
And it has also been suggested to be a marker of testicular
and germ cell malignancies [19,31-33]. These findings
show the biological importance of AP-2γ in human neo-
plasia. In our study, the AP-2γ-ChIP fragments were
obtained from human breast cancer cell line MDA-MB-
453 with high malignant degree; knock-down of AP-2γ
expression in MDA-MB-453 cells by siRNA decreased the
expressions of ErbB2, CDH2, IGSF11 and HPSE (Figures
6A and 7), but overexpression of AP-2γ in MDA-MB-231
cells elevated their mRNA and protein levels (Figures 6C
and 7). They are the direct regulatory targets of AP-2γ. Cur-
rent studies suggested that these four genes are all
involved in carcinogenesis. In human breast cancer, ErbB-
2 is overexpressed in 25–30% of all cases, and is represent-
ing a clinical marker of poor prognosis [34]; CDH2 pro-
motes tumor cell survival, migration and invasion, and its
high expression is often associated with poor prognosis
[35]; IGSF11 expression is elevated in colorectal cancers,
AP-2γ affected the expressions of ErbB2, CDH2, IGSF11 and HPSE at mRNA levels Figure 6
AP-2γ affected the expressions of ErbB2, CDH2, IGSF11 and HPSE at mRNA levels. The mRNA levels of ErbB2, 
CDH2, IGSF11 and HPSE were examined using Q-RT-PCR method while suppressing endogenous AP-2γ expression in MDA-
MB-453 cells (A); or overexpressing AP-2γ in HBL-100 cells (B) and in MDA-MB-231 cells (C). β-actin was used as an internal 
control to normalize the expression of each target mRNA. Relative gene expression was presented as mean ± SD from tripli-
cated independent experiments. (* means P < 0.01)BMC Cancer 2009, 9:279 http://www.biomedcentral.com/1471-2407/9/279
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hepatocellular carcinomas and intestinal-type gastric can-
cers [36]; HPSE plays a key role in the metastasis of solid
tumors as well as mediating tumor angiogenesis by both
directly promoting endothelial cell migration and indi-
rectly releasing proangiogenic molecules from the ECM
[37-39]. They probably mediate the effects of AP-2γ on the
tumor progression. In human mammary carcinoma, AP-
2γ may also functionally interact with these genes to influ-
ence tumor progression besides transcriptionally activat-
ing their expressions.
Overexpression of AP-2γ in HBL-100 and MDA-MB-231
presented different results on regulating ErbB2, CDH2
and IGSF11 (Figures 6B and 6C), indicating that the tran-
scriptional regulation network are complex. Similarly,
although the regulation patterns for most of the other 17
identified genes were revealed identical using the two
complementary approaches – overexpressing AP-2γ in
MDA-MB-231 and silencing AP-2γ in MDA-MB-453
(Additional file 6), upon closer examination, there are
some inconsistencies. In particular, for AAK1 (Adaptor
protein 2-associated kinase 1), overexpression of AP-2γ
results in a 4-fold increase in AAK1 expression, while there
is no decrease in AAK1 expression in the siRNA experi-
ment. This also implies the complexity of the regulation of
AAK1 by AP-2γ. Transcription factors (TFs) directly con-
trol gene expressions by interacting with cis-elements, but
transcription regulators (TRs) only assist to control gene
expression through interacting with TFs, remodeling chro-
matin, or other mechanisms. Both types of proteins con-
stitute master controllers of dynamic transcriptional
networks. In different cell lines, transcriptional regulation
networks might be different.
Conclusion
In summary, AP-2γ coordinates the expressions of a net-
work of genes, involving in carcinogenesis, especially in
breast cancers. Our data might contribute to better under-
standing the controversial findings concerning the role of
transcription factor AP-2γ in human breast cancer. The
novel AP-2γ target genes could serve as therapeutic targets
for anticancer therapy.
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AP-2γ expression alterations changed the ErbB2, CDH2, and  HPSE protein level in breast cancer cells Figure 7
AP-2γ expression alterations changed the ErbB2, 
CDH2, and HPSE protein level in breast cancer cells. 
MDA-MB-453 cells were transfected with negative control 
siRNA(Lane 1) and with AP-2γ siRNA (Lane 2). HBL-100 cells 
were transfected with negative control pCMV-Myc (Lane 3) 
and with pCMV-Myc-AP-2γ (Lane 4). MDA-MB-231 cells 
were transfected with negative control pCMV-Myc (Lane 5) 
and with pCMV-Myc-AP-2γ (Lane 6). The housekeeping gene 
GAPDH was used as an internal control.BMC Cancer 2009, 9:279 http://www.biomedcentral.com/1471-2407/9/279
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